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Abstract 
Context: Current therapy for renal cell carcinoma (RCC) generally consists of the sequential 
administration of single agent therapy. Given the advent of T-cell checkpoint inhibitors, the 
role of combinations including these agents is being intensely interrogated.  
Objective: To evaluate ongoing trials of combinations including immunotherapy and 
sequencing of agents to treat RCC. 
Evidence Acquisition: Recent data and ongoing trials were analysed to evaluate the direction 
of research in this arena. 
Evidence Synthesis: The favourable therapeutic index of PD-1/PD-L1 inhibitors enables 
combinations of these agents. Multiple ongoing phase III trials are evaluating the first-line 
therapy of RCC using a combination of PD-1/PD-L1 inhibitors with VEGF inhibitors or CTLA-
4 inhibitors. The role of sequencing using single agent sunitinib and avelumab will be 
evaluated in a randomized phase II trial. The role of vaccine therapy remains unproven. The 
role of predictive biomarkers to select appropriate therapy requires a larger focus, given the 
multitude of possible therapies. 
Conclusion: Therapy for RCC should be tailored based on both patient and tumour 
characteristics. Combination therapy and sequencing of single agents may both play roles 
and are undergoing clinical trial evaluation.  
Patient Summary: Combinations of immunotherapy with angiogenesis inhibitors is 
undergoing vigorous clinical trial evaluation. Sequencing of immunotherapy and anti-
angiogenic therapy is also undergoing investigation. Clinical trial participation is critically 
important to develop new drugs and combinations, and biomarkers to select therapy.  
 
Take home message 
The thrust of ongoing clinical research is to combine PD-1 and PD-L1 inhibitors with either 
anti-angiogenic agents or with CTLA-4 inhibitors as first-line therapy for metastatic renal cell 
carcinoma (RCC). Sequencing of more tolerable single agent therapy may continue to play a 
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role in selected patients ineligible for combination therapy. Additionally, the role of candidate 
predictive biomarkers requires validation. 
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Introduction 
Renal cell carcinoma (RCC) is exquisitely resistant to chemotherapy. The chemoresistance 
may be partly attributable to the disease being derived from proximal tubules, which express 
large amounts of the multidrug resistant P-glycoprotein. Equally, relative to other 
malignancies, RCC has been particularly sensitive to immunotherapy. The first indication 
that RCC might be a good target for immunotherapy came from the observation that patients 
with metastatic RCC occasionally experienced spontaneous regressions after surgical 
removal of the primary tumour [1–3]. It is also well established that there is profuse 
inflammatory infiltrate in RCC, although the precise role of each infiltrating cell type (T-cells, 
natural killer cells, dendritic cells and macrophages) is not established [4]. Until 2005, the 
median survival of patients with metastatic RCC (mRCC) was approximately 1 year and the 
only treatments available were interleukin (IL)-2 and interferon (IFN)-α which conferred 
modest benefits [5].  A major step-forward started in 2005, when new targeted drugs 
including mammalian target or rapamycin (mTOR) inhibitors (everolimus, temsirolimus), 
vascular endothelial growth factor (VEGF) inhibitors (sunitinib, sorafenib, axitinib, pazopanib, 
cabozantinib) and a programmed death (PD)-1 inhibitor (nivolumab) were approved [6,7]. 
Additionally, the combination of a VEGF inhibitor plus cytokine (bevacizumab plus IFN-α) 
and VEGF inhibitor plus mTOR inhibitor (lenvatinib plus everolimus) have demonstrated 
improved outcomes in the first-line and post-VEGF inhibitor settings respectively, and are 
approved. Thus, the treatment algorithm includes the use of sunitinib, pazopanib, 
bevacizumab plus IFN-α or temsirolimus as first-line therapy, and nivolumab, cabozantinib, 
axitinib or lenvatinib plus everolimus as second-line therapy. Collectively, these agents have 
extended the median survival of mRCC patients to 2-2.5 years. High dose IL-2 is reserved 
as first-line therapy for well selected younger patients without comorbidities. 
 
Since 2015, there has been a further paradigm shift in the management of mRCC with the 
addition of nivolumab, a T-cell checkpoint inhibitor, to the therapeutic armamentarium for 
post-VEGF inhibitor patients. The next generation of immunotherapeutics has been 
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established to be of benefit in mRCC. Harnessing the immune system has long been of 
interest because of the potential for durable responses, initially seen with cytokine treatment 
[8]. The step change in mechanism of action that T-cell checkpoint inhibitors provide is that 
of immunoediting i.e. altering the balance between the tumour and the immune system [9]. 
In the elimination phase CD8+ T-cells and natural killer cells destroy a proportion of 
malignant cells, the surviving cancer cells survive in a constrained state in the presence of 
immune cells in the equilibrium phase, before entering the escape phase where cancer cells 
evade immune cell recognition [9]. T-cell checkpoint inhibitors such as PD-1 inhibitors can 
alter this balance by unleashing the anti-tumour activity of T-cells in the tumour 
microenvironment [10].  
 
It remains the case that most patients will not show a major durable response to single line 
immune therapy [11]. As such, combination and sequential therapies are being evaluated. 
Vanneman and Dranoff have described different potential mechanisms by which 
combination therapy strategies may work [12]: (i) enhance antigen presentation and T-cell 
priming; (ii) augment differentiation of memory T cells; (iii) improve antitumour T-cell 
function; (iv) enhance cytotoxic T lymphocyte (CTL)-mediated lysis of tumour cells; (v) 
reduce tumour-associated immunosuppression; and (vi) decrease immunosuppressive cell 
populations. 
 
In view of the increasing number of drugs with differing mechanisms of action in the arsenal 
of the oncologist, the next questions being answered by clinical trials are the role of 
sequential or combinatorial therapy with immunotherapeutic agents. Ongoing trials are 
evaluating the combination of PD-1/PD-ligand (L)-1 inhibitors with either VEGF inhibitors or 
cytotoxic T-Lymphocyte Antigen (CTLA)-4 inhibitors as first-line therapy (Table 1). In this 
review, we will summarize this literature and plot a future course.   
 
Evidence acquisition 
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Search criteria 
A literature search was performed using Pubmed (January 1976-March 2017).  
 
The Past: cytokines and historically evaluated combinations  
Interferon-alpha (IFN-) and high-dose (HD) IL-2) are the two cytokine therapies which have 
been proven to be efficacious in mRCC treatment [13]. The exact mechanism by which 
these agents work is unclear. However, IL-2 is known to stimulate T-cell proliferation and 
differentiation and IFN- is antiangiogenic as well as a promoter of antigen presentation and 
dendritic cell development [4]. IL-2 is a toxic regimen, requiring inpatient administration and 
resulting in up to 3% patients dying from treatment; however, there is a 7% complete 
response (CR) rate, most of them being durable and potential cures, and around 15% 
patients have an objective response [14]. Unsurprisingly, toxicity has limited the use of this 
agent.  
 
In view of the potential for durable CR in patients treated with HD IL-2, predictive clinical and 
molecular markers of response have been evaluated in an effort to target this very toxic 
treatment to the right patients. Several retrospective studies determined that high carbonic 
anhydrase 9 (CA9) levels as measured by immunohistochemistry could predict which 
patients would respond to HD IL-2 [15,16]. These studies led to the prospective SELECT 
trial [17] which assessed the predictive ability of favourable histology [18] (alveolar features 
and no granular or papillary features) and high CA9 levels in 120 patients. Combined 
pathological features and CA9 levels was not proven to predict response to HD IL-2 [17].  
However, in a post-hoc analysis, combined single nucleotide polymorphisms (SNPs) in the 
Fc-gamma receptors (FCGRs): FCGR2A, FCGR3A, and FCGR2 was associated with 
outcome following HD IL-2 therapy [19].  
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Combination cytokine and VEGF inhibitor therapies have been evaluated, with bevacizumab 
(a monoclonal antibody targeting VEGF) being approved for use as first-line therapy in 
combination with IFN- [20,21]. Bevacizumab has also been combined with HD IL-2 and 
was found to be feasible, but did not appear to enhance durable responses over historical 
rates observed with IL-2 alone [22]. However, VEGF tyrosine kinase inhibitor (TKI) plus 
cytokine and VEGF inhibitor plus mTOR inhibitor combinations have historically 
demonstrated prohibitive toxicities and/or not resulted in additional long term responses 
compared with single agent cytokines [23–26]. In contrast to the lack of feasibility of these 
combinations of older VEGF inhibitors with mTOR inhibitors, the combination of lenvatinib (a 
VEGF and fibroblast growth factor receptor inhibitor) and everolimus was associated with a 
significantly longer median progression-free survival (PFS) of 14.6 months compared to 5.5 
months with everolimus alone in a randomized phase II trial [27].   
 
Vaccines  
As tumours progress they induce immune tolerance by loss of expression of tumour 
antigens and expression of checkpoint ligands leading to T-cell exhaustion. Viral vaccines 
have been designed to express pre-selected shared tumour antigens, which lead to 
activation of anti-tumour T-cells. The TroVax Renal Immunotherapy Survival phase III Trial 
evaluated standard of care alone or with a modified vaccinia Ankara encoding the tumour 
antigen 5T4 (MVA-5T4) for the treatment for mRCC [28]. Unfortunately, significant difference 
in overall survival was not observed, although, the magnitude of 5T4-specific antibody 
response and normal hematologic parameters (platelet, monocytes, haemoglobin) were 
associated with better survival. 
 
Following on from phase 1 and 2 studies demonstrating safety and correlation between 
immunological response and clinical outcomes [29,30], IMPRINT was a phase 3 study of the 
IMA901 vaccine with 10 tumour antigens (9 binding HLA-A*02 and 1 binding HLA-DR) 
known to be overexpressed on RCC [31]. Uniquely, this trial investigated the combination of 
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a vaccine with a VEGF inhibiting TKI. Vaccination with IMA901 plus GM-CSF and sunitinib 
were compared with sunitinib alone in HLA-A*02 positive mccRCC patients. The median OS 
was 33 months for the vaccine combination and was not reached for sunitinib. PFS was 15 
months for both arms. As such, despite promising early phase data the phase 3 study did 
not meet its primary endpoint. Interestingly, the T-cell response in the phase 3 study was 
three times less than that of the phase 1/2 studies of IMA901 [32].  
 
The phase 3 ADAPT trial (NCT01582672) is due to report and combines a customized 
patient-specific dendritic cell vaccine (AGS-003) with or without sunitinib. Previous 
preclinical studies that sunitinib suppressed myeloid derived suppressor cells (MDSCs) 
probably mediated by STAT3 inhibition, suggesting potential synergism with immunotherapy 
[33,34]. AGS-003 is composed of mature dendritic cells collected by leukapheresis, which is 
then electroporated with mRNA derived from patient’s tumour and with CD40 ligand. There 
is great interest in the result of this combination study as the phase 2 study demonstrated a 
good median OS of 30 months for combined vaccine and sunitinib [35].     
 
These collective results indicate no role for vaccines in mRCC currently, as stand alone or in 
combination with VEGF TKIs. However, there are no phase III study results combining 
vaccines with T-cell checkpoint inhibitors. There are issues over the cost of patient specific 
vaccine products and also over the potential for changes in trial comparator agents from 
TKIs to T-cell checkpoint inhibitors as first line therapy for mRCC when much anticipated 
first line checkpoint inhibitor trials readout soon [32].   
 
T-cell checkpoint inhibitor combination of PD-1/PD-L1 and CTLA-4 inhibitors 
PD-1/PD-L1 inhibitors lend themselves to combinations owing to their excellent therapeutic 
index, with grade ≥3 toxicities in only 15-20% of patients. The CTLA-4 receptor is essential 
for the function of CD4 T-regulator cells which are the key cells enabling self-tolerance. 
Whereas, PD-1 is an inhibitory receptor expressed on T-cells which when bound to its ligand 
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PD-L1 on tumour cells dampens the effect of CD8 T-cells and can cause exhausted T-cells. 
Figure 1 illustrates that CTLA-4 and PD-1/PD-L1 inhibitors work in different components of 
the cancer-immunity cycle, suggesting that this combination is non-redundant [36]. One of 
the first phase 3 trials in this arena was in advanced, previously untreated melanoma where 
combination CTLA-4 (ipilimumab) and PD-1 (nivolumab) inhibition resulted in an objective 
response rate (ORR) of 57.6% for combination therapy compared to 43.7% and 19% with 
nivolumab and ipilimumab monotherapies respectively [37]. Pre-clinical work had 
established that the potency of this combination therapy was likely due to the fact that the 2 
agents work on difference cell types. Interestingly in both mouse and cell line models, this 
same effect was not seen with sequential therapy [38].  
 
In mRCC, the phase I CHECKMATE 016 trial (NCT01472081) and expansion phase of that 
study assessed the combination of nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 
inhibitor) in the first (53%) and second line (47%) setting, using two different dosing 
regimens [39]. The ORR was 40% for nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (N3I1) 
and nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (N1I3). In both groups 83% had either CR, 
PR or SD. The N3I1 appeared more tolerable and yielded CR in 10% patients, with many 
patients exhibiting durable responses [39]. However, the combination does produce a 
greater risk of toxicities with grade ≥3 toxicities in approximately 40 to 60% of patients when 
examining patients across different malignancies. Nevertheless, these promising response 
data triggered a phase III U.S. Intergroup trial comparing first-line nivolumab combined with 
ipilimumab vs sunitinib (CHECKMATE 214; NCT02231749) [40].  
 
Immune and targeted drug combinations 
When considering the cancer-immunity cycle (figure 1), various oncology drugs can interfere 
with potentially beneficial effects for the mRCC patient [36]. There is a strong biological 
rationale for combining immunotherapy with VEGF targeting agents (i.e. sunitinib,  axitinib, 
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bevacuzimab) as the latter agents can promote infiltration of T-cells into tumours and 
facilitate synergism with PD-1 or PD-L1 inhibitors.   
 
The story in human studies is as follows. Phase 1 studies of nivolumab plus sunitinib or 
pazopanib in mRCC showed PFS rate at 24 weeks was 78% for sunitinib arm and 55% for 
the pazopanib arm [41]. However, there were 4 dose limiting toxicities (elevated ALT/AST 
[n=3], fatigue [n=1]) in 20 patients treated with pazopanib resulting in closure of this arm of 
the study. In contrast, a phase 1b study in the first line mRCC setting investigating the 
combination of avelumab and axitinib demonstrated feasibility and clinical benefit in all 6 
patients studied, with partial response in 5 patients [37]. These results have provided a 
rationale to undertake a phase 3 study of avelumab combined with axitinib vs sunitinib [43]. 
 
An alternative combination of atezolizumab (PD-L1 inhibitor) and bevacizumab in previously 
untreated mRCC in a phase 1 study demonstrated partial responses in 4 of 10 patients, with 
an additional 4 patients having prolonged stable disease [44]. Historical ORR for 
atezolizumab and bevacizumab are 15% and 9% respectively [44].  In correlative work from 
this study, intra-tumoural CD8+ T cells were found to increase following combination 
treatment, suggesting that the anti-VEGF and anti-PD-L1 combination improves antigen-
specific T-cell migration [44]. Ongoing studies using this combination include: phase II trial 
(NCT01984242) of atezolizumab monotherapy vs atezolizumab plus bevacizumab vs 
sunitinib and a phase III trial of atezolizumab plus bevacizumab vs sunitinib 
(NCT02420821).The randomized phase II trial was recently reported and demonstrated no 
overall statistical differences in PFS, but patients with PD-L1 positive tumours demonstrated 
a trend for extension of PFS with the combination vs sunitinib (HR=0.65, p=0.095) [45]. 
 
Evidence synthesis 
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There is no evidence regarding the optimal sequencing of TKIs and immunotherapy. Indeed, 
despite the strategy of combining agents, a substantial proportion of patients will be 
ineligible for more toxic combinations and may warrant the serial delivery of single agents. 
The randomized phase 2 SUAVE trial (figure 2) will compare avelumab (PD-L1 inhibitor) 
followed by sunitinib on PD vs sunitinib followed by avelumab on PD, and evaluates 
biomarkers to guide future development and therapy. Given the difficulty of comparing the 
multitude of possible sequences of multiple lines of therapy, a definitive resolution to the 
conundrum is unlikely.  
 
In other malignancies, expression of PD-L1 on cancer cells or infiltrating immune cells has 
been both prognostic and predictive. However, in RCC the expression of PD-L1 has been 
found to be highly variable. This is likely due to a mixture of factors: different antibodies, 
differing staining patterns (membrane vs cytoplasm), differing cut-offs for expression, 
whether cancer cell or immune cell expression is assessed [9]. In the 2nd line phase 3 trials 
of PD-1 inhibitors undertaken to date expression of PD-L1 appeared prognostic for worse 
survival, but was not predictive. In combination studies with a VEGF TKI, PD-L1 status was 
inversely correlated with response [41].  
 
Phase 2 studies where pre- and post-therapy tissue samples have been obtained may be 
the ideal setting to develop correlative biomarkers, both prognostic/predictive biomarkers 
and mechanism of resistance. Indeed, insights into early emerging pathways mediating 
resistance may assist with developing optimal combinations. Ball et al have undertaken a 
study comparing 4 exceptional responders to nivolumab with 3 patients with primary 
refractory disease [46]. The results demonstrated an increased CD8 lymphocyte infiltrate, 
number of somatic mutations, mutation associated neoantigens and expression of pro-
inflammatory immune transcripts in exceptional responders compared to patients with 
primary refractory disease. As with all molecular studies there is a need for extensive 
independent validation before a biomarker has truly been developed [47]. 
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Considering combination and sequential therapy with immunooncology agents there will be 
an increasing need to advance the development of predictive biomarkers in order to 
rationalize the multitude of potential combinations available for each patient. Molecular 
factors to select for efficacy and toxicity are not ready for routine use, but in the long term 
will hopefully make precision medicine possible. In the absence of validated predictive 
biomarkers, physicians should probably attempt to deliver as many lines of therapy as 
possible based on approved indications. Trials should be offered for every line of therapy 
since cure is unlikely with current therapy. 
 
Conclusions 
 
It remains to be established if combination of immunotherapy agents will provide a 
synergistic response in RCC as is the case in other diseases such as melanoma. If they do, 
then it may be that combinatorial therapies become the standard of first line care. If not and 
they are merely additive then the sequencing of agents will need to be more closely 
established as this may alter efficacy but reduce toxicity. Nevertheless, sequencing of single 
agents may continue to play a major role in patients unable to tolerate combination therapy 
due to comorbidities or suboptimal performance status.  
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Table 1. Ongoing randomized phase III combination T-cell checkpoint inhibitor trials in 
metastatic ccRCC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therapeutic target 
  
Line Control arm Experimental arm(s) 
PD-1 and CTLA-4 First Sunitinib Nivolumab + Ipilimumab x 4  
Nivolumab 
PD-1 and VEGF First Sunitinib Bevacizumab + Atezolizumab 
PD-L1 and VEGF First Sunitinib Axitinib + Avelumab 
PD-L1 and VEGF First Sunitinib Axitinib + Pembrolizumab 
VEGF/FGF and (PD-1 or 
mTOR) 
First Sunitinib Lenvatinib + Pembrolizumab OR 
Lenvatinib + Everolimus 
Vaccine (Dendritic cell-
based vaccine + 
autologous tumour cell 
mRNA + CD40 ligand) 
First Sunitinib Sunitinib + AGS-003 
 18 
Figure 1. The cancer-immunity cycle and effect of therapies 
 
The process of generation of immunity is cyclical and leads to factors which stimulate the 
immune system to produce a T-cell response. Conversely, there are also immune-inhibiting 
factors which regulate immunity. Beneath each of the 7 steps of the cancer-immunity cycle 
are examples of therapies that may interplay at that point [36]. Abbreviations: GM-CSF, 
granulocyte macrophage colony-stimulating factor; CARs, chimeric antigen receptors (taken 
from [36] with permission). 
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Figure 2. Design of SUAVE trial 
 
 
